Phase IIB trial of oral midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3 Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Agents
  • Leukemia, Myeloid, Acute
  • Myelodysplastic Syndromes
  • Staurosporine
  • fms-Like Tyrosine Kinase 3

abstract

  • These results suggest that midostaurin has hematologic activity in both patients with FLT3-mutant and wild-type. The degree of clinical activity observed supports additional studies that combine midostaurin and other agents such as chemotherapy especially in FLT3-mutant AML.

publication date

  • October 2010

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC4135183

Digital Object Identifier (DOI)

  • 10.1200/JCO.2010.28.9678

PubMed ID

  • 20733134

Additional Document Info

start page

  • 4339

end page

  • 45

volume

  • 28

number

  • 28